Osaka, Japan and Utrecht, the Netherlands
May 4th, 2020
In a world with COVID-19 travel restrictions, MILabs has remotely completed the installation of a new E-Class VECTor6 system at the Osaka University of Pharmaceutical Sciences, Osaka, Japan. With the help of a local technician, this top-of-the-line multimodality PET/SPECT/CT system was put into operation by remote control from MILabs’ support facility in the Netherlands.
According to Prof. Takashi Temma, Ph.D., Director of the Department of Biofunctional Analysis: “We are impressed by the robust design and remote support capabilities of this complex multimodal PET-SPECT-CT system. Besides delivering excellent imaging performance for each modality, the system also has the unique ability to run two assays labeled with different PET isotopes or PET/SPECT isotopes concurrently, in the same animal. Since we develop new diagnostic probes for biofunctional analysis, this MILabs system gives us the power advantage of within-subjects designs, resulting in more reliable results and the use of fewer disease models.”
Prof. Frederik Beekman, Ph.D., CEO/CSO comments: “We are excited that despite travel bans, we could get Prof. Temma’s system up and running for his routine use through remote control from our offices. The unique concurrent imaging capabilities of this multimodal system enables in a single imaging session to deliver more statistically reliable results than any other multimodal in-vivo imaging setup.”
About Osaka University of Pharmaceutical Sciences
The Osaka University of Pharmaceutical Sciences is dedicated to education and research in pharmaceutical sciences. Among its research objectives are the development of diagnostic and therapeutic methods using animal disease model by employing molecular imaging for early functional diagnosis, and evaluation of therapeutic effects on cancers. More specifically, the Biofunctional Analysis laboratory is focused on the design and development of radiolabeled probes for PET and SPECT imaging.
About MILabs B.V.
This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging either as stand-alone or fully integrated modalities on a single integrated system. For the commercialization of this preclinical imaging platform, MILabs was awarded the Commercial Innovation of the Year 2018 at the World Molecular Imaging Congress. For more information, visit: www.milabs.com or contact MILabs at [email protected]